Roughly one in five people who complete a course of isotretinoin (originally sold as Accutane) will see their acne return. A large cohort study of nearly 20,000 patients found a relapse rate of about 22.5%, while reviews spanning three decades of use suggest that 70 to 80 percent of patients achieve long-term remission after a single course. Those numbers sound reassuring until you are in the group whose skin flares up again, sometimes within months of finishing treatment. What determines whether you relapse, and what you can do about it, turns out to depend on a mix of dosing, biology, and what you do after your last pill.
How Common Relapse Actually Is
Relapse numbers vary across studies partly because researchers define “relapse” differently. Some count any return of acne lesions, others require a return severe enough to restart prescription treatment. A 2024 cohort study in JAMA Dermatology tracked 19,907 patients and found that 22.5% experienced acne relapse while 8.2% went back on isotretinoin for a second course.1PubMed Central. Acne Relapse and Isotretinoin Retrial in Patients With Acne That gap between the two figures is telling: many people who relapse manage their returning acne with milder treatments like topical retinoids or antibiotics rather than repeating the full isotretinoin experience.
A 30-year review of isotretinoin use concluded that long-term remission occurs in 70 to 80 percent of patients after a single course.2PubMed. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Put another way, roughly one in four or five people should expect some degree of return. Those odds are much better than any other acne treatment offers, but they also mean relapse is not a rare complication. It is a normal, well-documented outcome that dermatologists plan around.
Why Acne Comes Back After Isotretinoin
Isotretinoin works in large part by dramatically shrinking sebaceous glands, the tiny oil-producing structures in your skin that fuel acne when they go into overdrive. During a standard course, sebum production drops by roughly 88%.3Archives of Dermatology. Isotretinoin in the Treatment of Acne: Histologic Changes, Sebum Production, and Clinical Observations After treatment stops, those glands slowly recover. In some patients, sebum production rebounds to near pre-treatment levels within about 30 weeks. In others, the glands remain suppressed for well over a year. A study tracking patients for more than 80 weeks after their last dose found that roughly half still had 30 to 80 percent less sebaceous gland activity than they started with, while the rest had returned to baseline.4PubMed. Changes in long-term sebum production from isotretinoin therapy
This variability in gland recovery goes a long way toward explaining why some people stay clear indefinitely while others break out again. But sebum alone is not the full story. Isotretinoin also shifts the population of skin bacteria. Research has shown that it selectively alters the diversity of Cutibacterium acnes strains living in hair follicles, and that specific shifts in strain composition correlate with how well treatment works.5PubMed Central. Treatment response to isotretinoin correlates with specific shifts in Cutibacterium acnes strain composition within the follicular microbiome When sebaceous glands ramp back up and the bacterial ecosystem re-establishes itself, the conditions that originally caused acne can reassemble, particularly if underlying hormonal or genetic drivers are still present.
Who Is Most Likely to Relapse
Several patient characteristics consistently predict higher relapse risk. Younger age is one of the strongest. Patients who are 20 or younger at the time of treatment have significantly higher relapse rates, likely because their hormonal environment is still in flux.6PubMed. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris Sex also matters, though the direction depends on what you measure. The JAMA Dermatology cohort study found that female sex was associated with a higher rate of acne relapse overall.7PubMed Central. Acne Relapse and Isotretinoin Retrial in Patients With Acne Meanwhile, a Spanish study following 142 patients found the risk of relapse was twice as high among men.8Actas Dermo-Sifiliográficas. Acne Relapse Rate and Predictors of Relapse Following Treatment with Oral Isotretinoin This apparent contradiction likely reflects differences in study populations, definitions of relapse, and follow-up length. The practical takeaway is that both men and women face meaningful relapse risk, though the specific drivers differ.
The type and severity of acne at the start of treatment also matter. Patients with macrocomedone-type acne, the kind dominated by large, stubborn plugged pores, tend to relapse more often.9PubMed. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris Patients who still had residual lesions when they stopped isotretinoin were also at higher risk, suggesting that finishing the course before skin is genuinely clear may leave the door open for a faster return. In a study of nodulocystic acne, the number of nodules at the start of treatment predicted relapse during the first year, while first-year relapse in women was also linked to how many inflammatory lesions remained at the end of treatment.10PubMed. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse
The Cumulative Dose Question
Dermatologists have debated for decades whether a higher total dose of isotretinoin translates to lower relapse risk. The traditional target has been a cumulative dose of 120 to 150 mg/kg spread over five to six months. A 2014 study in JAMA Dermatology compared patients who received less than 220 mg/kg with those who received 220 mg/kg or more. The lower-dose group had a relapse rate of about 47%, compared to roughly 27% in the higher-dose group, a statistically significant difference.11JAMA Dermatology. High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris That study helped push some dermatologists toward prescribing higher cumulative doses.
The picture is not as clean-cut as that single study implies, though. A randomized controlled trial comparing cumulative doses of 120 mg/kg versus 150 mg/kg found nearly identical relapse rates at 12 months after treatment: about 27% and 32%, respectively, a difference that was not statistically meaningful.12PubMed Central. Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial And the large JAMA Dermatology cohort found that while higher cumulative dose was associated with lower relapse at a population level, the daily dose during treatment did not independently affect relapse risk.13PubMed Central. Acne Relapse and Isotretinoin Retrial in Patients With Acne
What this all suggests is that there is likely a floor below which relapse becomes more probable, and getting above that floor matters. But pushing the total dose much higher once you are past that threshold may not buy much additional protection. The argument for reaching at least 120 mg/kg is solid. The argument for routinely exceeding 200 mg/kg is more contested.
How Food and Absorption Affect Outcomes
Standard isotretinoin capsules are fat-soluble, meaning they absorb much better when taken with a meal that contains fat. This is not a minor detail. The oral bioavailability of traditional isotretinoin is highly variable and depends heavily on whether you eat when you take your pill. Patients who frequently take it on an empty stomach absorb significantly less drug than their prescription label implies, potentially ending up with a much lower actual cumulative dose than their dermatologist intended.14PubMed Central. Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses Some researchers have argued this variable absorption is one of the overlooked explanations for early relapse: patients who skip meals or take their pill with coffee and little else may technically complete a course but never actually reach the intended cumulative exposure.
Newer formulations have been designed to address this problem. A micronized version of isotretinoin uses smaller particle sizes to improve absorption regardless of food intake. An open-label study of lidose-isotretinoin, one such formulation designed to be taken without food, found that over a two-year follow-up period only about 4% of patients needed retreatment with isotretinoin, and roughly 83% required no additional acne treatment at all.15PubMed Central. An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period Those relapse numbers are at the low end of what studies have reported for traditional isotretinoin. The rationale is straightforward: if the drug absorbs reliably regardless of what you ate for breakfast, more patients will actually hit the cumulative dose their treatment plan intended.16PubMed Central. Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages
The Hormonal Factor, Especially PCOS
In women, hormonal drivers of acne can operate independently of everything isotretinoin does to the skin. Polycystic ovary syndrome is a common culprit. A study comparing isotretinoin outcomes in women with and without PCOS found that PCOS was a significant predictor of relapse during the second year after treatment, even when the initial response to isotretinoin looked equally good in both groups.17PubMed. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse The underlying excess androgens that drive PCOS-related acne remain in play after isotretinoin, so the skin eventually responds to those signals again once the drug’s effects wear off.
Research does show that isotretinoin itself can have some beneficial effects on hormonal markers in women with PCOS, including reductions in free testosterone levels.18PubMed Central. The Effects of Oral Isotretinoin in Women with Acne and Polycystic Ovary Syndrome But these effects are not permanent, and isotretinoin was never designed to treat PCOS. For women with confirmed or suspected hormonal acne, dermatologists often consider antiandrogen therapy as part of a maintenance plan after isotretinoin. The Spanish relapse study found that women who did not receive antiandrogen therapy had a 3.5-fold higher risk of relapse compared to those who did.19Actas Dermo-Sifiliográficas. Acne Relapse Rate and Predictors of Relapse Following Treatment with Oral Isotretinoin If you are a woman whose acne has hormonal features, asking your dermatologist about spironolactone or combined oral contraceptives as follow-up therapy is a reasonable conversation to have.
Maintenance Therapy After Your Course Ends
One of the more actionable findings in the relapse literature is that what you do after isotretinoin matters almost as much as the drug itself. Topical retinoids used as maintenance therapy have consistently shown a protective effect. That Spanish study quantified the benefit at about a 32% risk reduction for each month of topical retinoid use.20Actas Dermo-Sifiliográficas. Acne Relapse Rate and Predictors of Relapse Following Treatment with Oral Isotretinoin
A split-face study tested a topical retinoid combination against a vehicle (a cream with no active ingredient) applied to opposite sides of each patient’s face. After follow-up, the retinoid-treated side had a relapse rate of about 17%, versus 43% on the untreated side.21Actas Dermo-Sifiliográficas. Assessment of the Efficacy and Safety of a Combination of 2 Topical Retinoids (RetinSphere) in Maintaining Post-Treatment Response of Acne to Oral Isotretinoin That is a striking difference, and it came from a simple, well-tolerated topical product. A small case series using tazarotene lotion after isotretinoin found that none of the 12 patients who completed the protocol relapsed during an average follow-up of 13 months, and the tazarotene also appeared to improve the look of residual acne scarring.22PubMed Central. Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports
Despite this evidence, many patients finish isotretinoin and simply stop all acne treatment, either because their dermatologist did not recommend a maintenance plan or because they assume the drug has permanently solved the problem. The data strongly suggests that continuing a topical retinoid, even a mild one, can meaningfully extend the time before acne returns or prevent relapse entirely. It is one of the clearest practical steps you can take.
What a Second Course Looks Like
If your acne does come back and topical treatments are not enough, a second round of isotretinoin is a well-established option. The large JAMA Dermatology study found that about 8% of patients ultimately went back on the drug.23PubMed Central. Acne Relapse and Isotretinoin Retrial in Patients With Acne Second courses tend to work just as well as the first, and some dermatologists report that patients respond faster the second time around, possibly because the sebaceous glands never fully recovered from the first course.
The side effect profile on a second course is generally similar to the first. You will likely experience the same dry lips, dry skin, and occasional joint stiffness, and the same monitoring requirements for blood work apply. Women of reproductive age still need to follow strict pregnancy-prevention protocols. There is no evidence that a second course carries meaningfully greater risk than the first, though some patients find the side effects feel harder to tolerate the second time simply because they know what to expect and are less willing to endure months of discomfort again.
A third course is rarer but not unheard of. At some point, if acne keeps returning despite multiple courses, dermatologists start investigating whether an underlying hormonal condition, medication interaction, or other systemic factor is driving the recurrence. Persistent relapsers sometimes benefit from low-dose isotretinoin taken on a longer-term or intermittent basis rather than the standard high-dose course, though the evidence base for this approach is thinner. One randomized study found that low-dose and intermittent regimens had higher relapse rates than conventional dosing at one year.24British Journal of Dermatology. Effectiveness of conventional, low‐dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study So while low-dose maintenance is used in practice, it comes with a trade-off.
When Relapse Is Not Really Relapse
Worth mentioning is that not every post-isotretinoin breakout constitutes a true relapse. Mild, occasional pimples are a normal part of having skin. Many patients who went through isotretinoin for severe cystic acne have recalibrated their expectations to the point where any blemish feels like a failure. A few whiteheads or a monthly hormonal spot along the jawline is not the same as a return of widespread inflammatory acne, and it does not necessarily mean the drug failed or that you need another course.
True relapse in the clinical sense usually means a return of the type and severity of acne that originally warranted isotretinoin. If you are seeing scattered mild breakouts that respond to over-the-counter benzoyl peroxide or a prescription topical retinoid, that is a manageable situation and a very different thing from the deep, scarring lesions that brought you to isotretinoin in the first place. Discussing the distinction with a dermatologist can save you from unnecessary worry or from prematurely jumping back into a treatment with real side effects when a simpler approach would work.
Skin Bacteria and the Open Questions
One of the more interesting frontiers in understanding isotretinoin relapse involves the skin microbiome. As noted earlier, isotretinoin changes the composition of bacterial strains on the skin, and specific shifts in strain diversity have been linked to treatment response.25PubMed Central. Treatment response to isotretinoin correlates with specific shifts in Cutibacterium acnes strain composition within the follicular microbiome What researchers do not yet know is whether monitoring these bacterial shifts after treatment ends could help predict who will relapse. If certain strain patterns re-emerge in the months following isotretinoin and reliably precede a clinical flare, that could eventually allow targeted early intervention rather than the current approach of waiting for acne to visibly return.
There is also growing interest in how isotretinoin interacts with intracellular signaling pathways involved in oil production and inflammation. Some evidence suggests the drug’s effects extend beyond just shrinking oil glands to influencing gene expression in ways that suppress the inflammatory cascade. Whether those molecular effects persist or fade unevenly across patients is an open area of study, and it may eventually help explain why two patients with identical doses, identical treatment lengths, and similar acne severity can have completely different long-term outcomes. For now, the honest answer is that individual biology plays a large role, and predicting relapse at the individual level remains imprecise even for experienced dermatologists.